<p>CASI Pharmaceuticals Inc. reported third quarter 2025 revenues of $3.1 million, a 60% decrease from $7.8 million in the same period last year, mainly due to estimated returns of EVOMELA by its sole distributor under a modified agreement. Cost of revenue was $2.4 million, down 35% from $3.7 million. Research and development expenses were stable at $1.4 million compared to $1.5 million last year. General and administrative expenses decreased 14% to $4.9 million, while selling and marketing expenses declined 6% to $4.6 million. Net loss for the quarter increased to $10.9 million from $8.4 million. As of September 30, 2025, CASI had $4.7 million in cash and cash equivalents and 20.5 million shares outstanding. The company raised approximately $5.7 million from an at-the-market facility during the quarter. In June 2025, its subsidiary in Wuxi began production, with certain costs allocated to inventory. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102392) on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CASI

<p>CASI Pharmaceuticals reported Q3 2025 revenue of $3.1 million, a 60% drop from last year, due to EVOMELA returns. Net loss increased to $10.9 million. Costs decreased in several areas, with cash reserves at $4.7 million. The company raised $5.7 million and began production in Wuxi.</p>

CASI Pharmaceuticals Reports Third Quarter Revenue of $3.1 Million and Net Loss of $10.9 Million